RedHill Biopharma announces positive results of COVID-19 opaganib study
By Nikita Chaurasia  Date: 2021-01-05

RedHill Biopharma announces positive results of COVID-19 opaganib study

Israeli specialty biopharmaceutical company, RedHill Biopharma Ltd., has announced the preliminary data from the phase-2 clinical trials of its drug opaganib which was administered orally in patients suffering from COVID-19. The trial round included around 40 participants, with the study showing positive signals of efficacy and safety.

For the uninitiated, opaganib is an oral drug that acts as a sphingosine kinase-2 (SK2) inhibitor and is used for treating individuals with COVID-19 pneumonia. Its primary function is to target the host cell responsible for viral replication, thereby potentially minimizing the likelihood of viral resistance.

It is also worth mentioning that RedHill’s opaganib has received orphan drug designation by the U.S. Food & Drug Administration (FDA) for treating cholangiocarcinoma. The drug is currently being evaluated in a phase-2 study for the treatment of prostate cancer as well as cholangiocarcinoma.

If reports are to be believed, the preliminary data comes from a randomized, placebo-controlled, double-blind clinical trial round conducted on COVID-19 patients that required oxygen support. Furthermore, the trials found that there were no material safety differences between opaganib and the placebo treatment arms.

The drug reportedly demonstrated consistent progressive improvement in reducing oxygen requirements of the patients by the 14th day of the trial. Specifically, 52.6% of the patients in the opaganib group no longer required oxygen support as compared to 22.2% in the placebo group.

Medical director of RedHill Biopharma, Mark L. Levitt, was quoted saying that the organization expects the preliminary results from the recently conducted COVID-19 therapy study to support its global phase 2/3 study. The company will compile a robust data set for supporting the potential filing of emergency use applications, he added.

About RedHill Biopharma Ltd.

Since its inception in 2009, Redhill Biopharma primarily focuses on the treatment of gastrointestinal and other infectious diseases. The company’s products are based on several technology platforms and are known to be more affordable than other chemical entities under development.

Source credits –

https://www.prnewswire.com/news-releases/redhill-biopharma-annonce-les-resultats-positifs-de-la-phase-2-de-l-etude-covid-19-sur-l-opaganib-en-termes-de-securite-et-d-efficacite-845306278.html

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

ClaimBuddy secures undisclosed sum in Titan Capital-led funding round
ClaimBuddy secures undisclosed sum in Titan Capital-led funding round
By Nikita Chaurasia

Indian insurance technology startup ClaimBuddy has reportedly raised an undisclosed amount in a seed funding round which was led by Titan Capital and involved participation from other marquee investor groups including First Cheque as well as LV Angel...

Mercedes-Benz unveils the EQA SUV in a bid to outdo Tesla, Volkswagen
Mercedes-Benz unveils the EQA SUV in a bid to outdo Tesla, Volkswagen
By Nikita Chaurasia

Daimler AG owned German automotive giant, Mercedes-Benz, has reportedly introduced the EQA, a new electric compact SUV to compete with market leader Tesla, Inc. as well as to meet its carbon targets in China and Europe. The Mercedes-Benz EQA, one of...

New York planning on direct purchase of Pfizer’s COVID-19 vaccines
New York planning on direct purchase of Pfizer’s COVID-19 vaccines
By Nikita Chaurasia

In recent developments, Governor of New York, Andrew Cuomo has reportedly issued a letter to the CEO of American drug maker Pfizer Inc., Albert Bourla, requesting for direct purchase of COVID-19 vaccine doses. Although the company is not bound to any...

Mayo Clinic Laboratories forms alliance with American Hospital Dubai
Mayo Clinic Laboratories forms alliance with American Hospital Dubai
By Nikita Chaurasia

In recent developments, Minnesota-based Mayo Clinic Laboratories and American Hospital Dubai are reportedly planning on entering a strategic alliance which is aimed at enhancing advanced laboratory diagnostic services in Dubai. Under the terms of th...

LTI, IBM extend global partnership to spearhead digital transformation
LTI, IBM extend global partnership to spearhead digital transformation
By Nikita Chaurasia

The New York-headquartered IBM Corp., with its global partner Larsen Toubro Infotech, an Indian global IT solutions & services company, are planning to extend their multi-year partnership, in a bid to enable companies to revolutionize the busines...